Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Perceptive Instruments Earn Out Payment

13 Feb 2015 07:00

RNS Number : 8002E
Instem plc
13 February 2015
 



13 February 2015

Instem plc("Instem" or the "Company")

 

Perceptive Instruments Earn Out Payment

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that it has paid in full the performance based earn out of £300,000 in respect of the acquisition of Perceptive Instruments Limited ('Perceptive').

 

Earn Out Payment

As a result of Perceptive achieving all of the specified earn out targets for the period to 21 November 2014, the Vendors have been paid the maximum additional consideration of £300,000 in accordance with the Acquisition Agreement.

 

Background to the Acquisition

Instem acquired Perceptive in November 2013 for a maximum consideration of £1.3m, including the conditional earn out, marking the Company's entrance into the in vitro R&D marketplace.

 

Perceptive is located in Suffolk, UK, and develops, manufactures and supplies software and hardware products for in vitro study data collection and study management in the genetic toxicology, microbiology and immunology markets. Perceptive is the leading technology provider within its niche market and there are few competitors active in the space.

 

Phil Reason, CEO of Instem, said: "The acquisition of Perceptive has been a success, not only in terms of the financial contribution the acquisition has made to date, but also in terms of expanding the Company's offering into the in vitro data collection and study management in the genetic toxicology, microbiology and immunology markets We are looking forward to another strong contribution from this area in 2015 and beyond."

 

For further information, please contact:

Instem plc

Tel: +44 (0) 1785 825 600

Phil Reason, CEO

www.instem.com

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or

Paul Cornelius

instem@walbrookpr.com

Sam Allen

 

Nick Rome

 

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKAAFSDSEFF
Date   Source Headline
18th May 20071:09 pmRNSRule 8.3- Intnl Nuclear Sol.
17th May 20075:02 pmRNSRule 8.3- Int Nuclear Sol
17th May 20073:25 pmBUSRule 8.3 - International Nuclear Solutions
16th May 20079:13 amRNSNotification of shares
14th May 200710:40 amRNSEGM ADJOURNMENT
11th May 200711:48 amRNSHolding(s) in Company
11th May 20079:42 amRNSHolding(s) in Company
10th May 20073:04 pmBUSRule 8.3 - International Nuclear Solution
10th May 20071:44 pmRNSRule 8.3-Int'l Nuclear Sol
1st May 200711:44 amRNSHolding(s) in Company
1st May 200710:00 amRNSRule 8.3- Intnl Nuclear Sols
30th Apr 20074:26 pmRNSHolding(s) in Company
26th Apr 20073:29 pmBUSRule 8.3 - International Nuclear Solutions
26th Apr 20073:07 pmRNSRule 8.3-Intl Nuclear Sol
26th Apr 20072:28 pmRNSRule 8.3- Intl Molybdenum plc
25th Apr 20073:17 pmBUSRule 8.3 - International Nuclear Solutions
25th Apr 200712:41 pmRNSRule 8.3- Int'l Nuclear Sol
23rd Apr 20071:34 pmRNSRule 8.3-Int. Nuclear
20th Apr 20074:30 pmRNSPosting of Scheme Document
18th Apr 20073:32 pmBUSRule 8.3 - International Nuclear Solutions
18th Apr 200710:09 amRNSRule 8.3- Intnl Nuclear Sol.
12th Apr 20073:05 pmBUSRule 8.3 - International Nuclear Solutions
5th Apr 20075:02 pmBUSRule 8.3 - International Nuclear Solution
5th Apr 200711:39 amRNSRule 8.3- Intnl Nuclear Sol.
5th Apr 200711:00 amRNSRule 8.3- Intnl Nuclear Sol
4th Apr 20074:21 pmRNSRule 8.3- Int Nuclear Sol
4th Apr 20073:30 pmBUSRule 8.3 - International Nuclear Solutions
4th Apr 200711:47 amRNSRule 8.3- Intnl Nuclear Sol.
4th Apr 20077:02 amRNSRecommended Cash Offer
4th Apr 20077:02 amRNSScheme of arrangement
3rd Apr 20075:29 pmRNSCorrection to Prelims
30th Mar 20073:13 pmBUSRule 8.3 - International Nuclear Solutions
29th Mar 20073:21 pmBUSRule 8.3 - INTERNATIONAL NUCLEAR SOLUTIONS
28th Mar 20073:27 pmRNSRule 8.3-Int Nuclear Sol
27th Mar 20077:02 amRNSFinal Results
26th Mar 200711:37 amRNSRule 8.3- Intnl Nuclear Sol.
23rd Mar 20073:26 pmBUSRule 8.3 - International Nuclear Solutions
19th Mar 200711:06 amRNSRule 8.3- Intnl Nuclear Sol.
8th Mar 200711:59 amRNSRule 8.3- Intnl Nuclear Sol.
20th Feb 20072:34 pmBUSRule 8.3 - Internationa Nuclear Solutions
16th Feb 200710:50 amRNSRule 8.3- Intnl Nuclear Sol.
12th Feb 200712:06 pmRNSRule 8.3- Intnl Nuclear Sol.
7th Feb 20073:18 pmBUSRule 8.3 - International Nuclear Solutions
1st Feb 200710:40 amRNSRule 8.3- Intnl Nuclear Sol.
30th Jan 200711:01 amRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20072:39 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20071:51 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 200711:00 amRNSRule 8.3- Intnl Nuclear
26th Jan 20075:45 pmRNSShare Interest
26th Jan 20073:20 pmRNSRule 8.1- Int Nuclear Sols

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.